ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study

Haematologica. 2019 Feb;104(2):e65-e67. doi: 10.3324/haematol.2018.199844. Epub 2018 Sep 6.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bleomycin / adverse effects
  • Bleomycin / therapeutic use
  • Dacarbazine / adverse effects
  • Dacarbazine / therapeutic use
  • Doxorubicin / adverse effects
  • Doxorubicin / therapeutic use
  • Hodgkin Disease / diagnosis
  • Hodgkin Disease / drug therapy*
  • Hodgkin Disease / mortality
  • Humans
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Rituximab / administration & dosage
  • Treatment Outcome
  • Vinblastine / adverse effects
  • Vinblastine / therapeutic use

Substances

  • Bleomycin
  • Rituximab
  • Vinblastine
  • Dacarbazine
  • Doxorubicin

Supplementary concepts

  • ABVD protocol